{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-013272","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.823842+00:00","generated_at":"2026-06-17T00:39:44.439315+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assembly Bio reports positive Phase 1a data for ABI-4334; to partner core inhibitor portfolio, focus on ABI-5366","bullets":["ABI-4334 200 mg QD projected >30x protein-adjusted EC50 for cccDNA; half-life supports once-daily dosing.","Phase 1a safety: mild-to-moderate AEs, no pattern, no clinically significant ECG abnormalities.","Company will partner core inhibitor portfolio; no further internal clinical development for HBV cure.","Prioritizing ABI-5366 (genital herpes) with Phase 1 expected H1 2024; second candidate by end of 2024.","Cash runway extended into Q3 2024 due to reprioritization."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-013272","json":"https://secwatch.observer/filing/0000950170-23-013272.json","markdown":"https://secwatch.observer/filing/0000950170-23-013272.md","text":"https://secwatch.observer/filing/0000950170-23-013272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023013272/0000950170-23-013272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023013272/asmb-20230418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:39:44.439315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}